Journal
ANNALS OF MEDICINE AND SURGERY
Volume 77, Issue -, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.amsu.2022.103625
Keywords
Breast cancer; Biomarkers; Metabolomics; Early detection; Nipple aspirate fluid; Mass spectrometry
Categories
Ask authors/readers for more resources
The review examines the use of new technologies to evaluate the components of nipple fluid and their potential as biomarkers in screening.
New technologies can help identify metabolites that were previously difficult to identify in small volume fluids.
The discovery of biomarkers in nipple aspirate fluid is attractive for assessing high-risk patients, but current evaluation is limited by poor diagnostic accuracy.
Nipple aspirate fluid is the physiological biofluid lining ductal epithelial cells. Historically, cytology of nipple fluid has been the gold standard diagnostic method for assessment of ductal fluid in patients with symptomatic nipple discharge. The role of biomarker discovery in nipple aspirate fluid for assessment of asymptomatic and high-risk patients is highly attractive but evaluation to date is limited by poor diagnostic accuracy. However, the emergence of new technologies capable of identifying metabolites that have been previously thought unidentifiable within such small volumes of fluid, has enabled testing of nipple biofluid to be re-examined. This review evaluates the use of new technologies to evaluate the components of nipple fluid and their potential to serve as biomarkers in screening.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available